Skip to main content
Premium Trial:

Request an Annual Quote

Regulus to Raise $90M in Stock Offering

Premium

NEW YORK (GenomeWeb) — Regulus Therapeutics this week announced that it had priced its previously announced public offering of roughly 5.3 million shares of its common stock at $17 apiece, valuing the transaction at about $90 million.

During midday trading on the Nasdaq Wednesday, shares of Regulus were selling for $18.90 each.

About 4.4 million shares are being sold by Regulus, with the remainder being offered by former parent firm Isis Pharmaceuticals. The underwriters of the offering have also been granted an option to buy an additional 794,117 shares.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more